AI takes on kidney transplant rejection in new pilot trial
NCT ID NCT05432765
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether an AI-based system can help doctors choose the right doses of immunosuppressant drugs for kidney transplant patients. The goal is to protect the new kidney from damage and rejection. The study will enroll 34 adults who have received a deceased donor kidney transplant and need the drug tacrolimus. Researchers will measure changes in kidney scarring and function over 15 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida Health Shands
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Can your gut bacteria change how transplant drugs work?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- Your gut bacteria might predict transplant rejection